1156 related articles for article (PubMed ID: 33749547)
21. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
22. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.
Jo S; Kim H; Kim S; Shin DH; Kim MS
Chem Biol Drug Des; 2019 Dec; 94(6):2023-2030. PubMed ID: 31436895
[TBL] [Abstract][Full Text] [Related]
24. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
[TBL] [Abstract][Full Text] [Related]
25. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
26. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
Rehman MT; AlAjmi MF; Hussain A
Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
[TBL] [Abstract][Full Text] [Related]
27. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M
Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A
Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088
[TBL] [Abstract][Full Text] [Related]
28. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
29. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).
da Silva FMA; da Silva KPA; de Oliveira LPM; Costa EV; Koolen HH; Pinheiro MLB; de Souza AQL; de Souza ADL
Mem Inst Oswaldo Cruz; 2020; 115():e200207. PubMed ID: 33027419
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study.
Gorai S; Junghare V; Kundu K; Gharui S; Kumar M; Patro BS; Nayak SK; Hazra S; Mula S
ChemMedChem; 2022 Apr; 17(8):e202100782. PubMed ID: 35112482
[TBL] [Abstract][Full Text] [Related]
31. Potentiality of
Sen D; Bhaumik S; Debnath P; Debnath S
J Biomol Struct Dyn; 2022 Oct; 40(16):7517-7534. PubMed ID: 33719855
[TBL] [Abstract][Full Text] [Related]
32. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
33. Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivative.
Andrzejczyk J; Jovic K; Brown LM; Pascetta VG; Varga K; Vashisth H
Proteins; 2022 Nov; 90(11):1896-1907. PubMed ID: 35567429
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
[TBL] [Abstract][Full Text] [Related]
35. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
36. Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations.
Singh R; Bhardwaj VK; Das P; Bhattacherjee D; Zyryanov GV; Purohit R
Comput Biol Med; 2022 Jul; 146():105572. PubMed ID: 35551011
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
[TBL] [Abstract][Full Text] [Related]
38. A computational study on active constituents of
Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.
Khorsandi Z; Afshinpour M; Molaei F; Askandar RH; Keshavarzipour F; Abbasi M; Sadeghi-Aliabadi H
J Biomol Struct Dyn; 2022 Oct; 40(17):7940-7948. PubMed ID: 33784944
[TBL] [Abstract][Full Text] [Related]
40. Potential of (
El-Hawary SS; Issa MY; Ebrahim HS; Mohammed AF; Hayallah AM; El-Kadder EMA; Sayed AM; Abdelmohsen UR
Nat Prod Res; 2022 Jun; 36(11):2843-2847. PubMed ID: 33949276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
